Cosentyx, also known as secukinumab, is a biologic medication used to treat several chronic conditions, such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1][2]. The long-term effects of Cosentyx's consistent efficacy are primarily associated with its ability to manage the signs and symptoms of these conditions over an extended period.

Clinical trials and real-world evidence suggest that Cosentyx provides long-term benefits for patients with plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1][2][3]. Its efficacy in managing these conditions has been demonstrated in several studies, including those evaluating its long-term use.

For plaque psoriasis, Cosentyx has shown significant improvements in skin clearance and reduction of itchiness over 52 weeks, with sustained efficacy through 5 years of treatment [2]. Additionally, patients with psoriatic arthritis have demonstrated improvements in joint symptoms, physical function, and quality of life over 3 years of Cosentyx therapy [1]. Similarly, ankylosing spondylitis patients treated with Cosentyx have experienced improvements in disease activity, function, and quality of life for up to 5 years [3].

In terms of safety, Cosentyx has a well-established safety profile, with most adverse events being mild or moderate in severity [1][2][3]. Common side effects include upper respiratory tract infections, headaches, and diarrhea [1]. However, long-term safety data should be continuously monitored and evaluated in post-marketing studies.

In summary, Cosentyx's consistent efficacy in managing chronic conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis has demonstrated long-term benefits for patients, including improvements in symptoms, physical function, and quality of life. Its safety profile remains generally favorable, with most adverse events being mild or moderate in severity.

Sources:

[1] DrugPatentWatch. (n.d.). Cosentyx (secukinumab): Patent Expiration, Sales, and Competitor Analysis. Retrieved from <https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX>

[2] Reich, K., & Lebwohl, M. G. (2019). Long-term Efficacy and Safety of Secukinumab in Moderate-to-Severe Plaque Psoriasis: Pooled Analyses of Randomized Controlled Trials. American Journal of Clinical Dermatology, 20(5), 621-631. doi: 10.1007/s40257-019-00443-3

[3] Baraliakos, X., Braun, J., Deodhar, A., Burgos-Vargas, R., Ramiro, S., van der Heijde, D., ... & Moots, R. (2019). Long-term efficacy and safety of secukinumab in ankylosing spondylitis: 5-year results from the phase 3 MEASURE 1 trial. Annals of the Rheumatic Diseases, 78(10), 1513-1520. doi: 10.1136/annrheumdis-2019-215354